ECM
IMDX

Elgethun Capital Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Elgethun Capital Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-35
Closed -$5K – 176
2016
Q4 		$5K Buy
+35
New +$3.85K ﹤0.01% 241

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FM
Family Management New York $834M AUM 20.83% 1-Year Est. Return

Elgethun Capital Management's IMDX Position: Q1 2017 in Review

Elgethun Capital Management sold out of Insight Molecular Diagnostics (IMDX) in Q1 2017, closing a stake of 35 shares — an estimated $5K sold.

Elgethun Capital Management first reported a position in IMDX in Q4 2016 and held it in 1 quarter. The position peaked at $5K in Q4 2016. 33 funds tracked by Wall St. Rank hold IMDX as of Q1 2017.

  • Elgethun Capital Management reported no remaining Insight Molecular Diagnostics position as of Q1 2017 after selling out during the quarter.
  • Elgethun Capital Management sold 35 Insight Molecular Diagnostics shares in Q1 2017, an estimated $5K.
  • Elgethun Capital Management first reported a position in Insight Molecular Diagnostics in Q4 2016 and held it in 1 quarter.
  • Elgethun Capital Management's Insight Molecular Diagnostics position peaked at $5K in Q4 2016.
  • 33 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2017.

Based on Elgethun Capital Management's 13F filing for Q1 2017, filed 11 May 2017.